Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Elvitegravir: a once-daily inhibitor of HIV-1 integrase.

Wills T, Vega V.

Expert Opin Investig Drugs. 2012 Mar;21(3):395-401. doi: 10.1517/13543784.2012.658914. Review.

PMID:
22321026
2.

Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

Schrijvers R, Debyser Z.

Expert Opin Pharmacother. 2012 Sep;13(13):1969-83. doi: 10.1517/14656566.2012.712514. Review.

PMID:
22849516
3.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
4.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team..

Lancet. 2012 Jun 30;379(9835):2439-48. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

PMID:
22748591
5.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team..

Lancet. 2012 Jun 30;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0.

PMID:
22748590
6.

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL.

HIV Clin Trials. 2014 Sep-Oct;15(5):218-30. doi: 10.1310/hct1505-218.

PMID:
25350960
7.

Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

Lampiris HW.

Expert Rev Anti Infect Ther. 2012 Jan;10(1):13-20. doi: 10.1586/eri.11.157. Review.

PMID:
22149610
8.

Integrase inhibitors: a novel class of antiretroviral agents.

Schafer JJ, Squires KE.

Ann Pharmacother. 2010 Jan;44(1):145-56. doi: 10.1345/aph.1M309. Review.

PMID:
20040702
9.

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.

White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD.

Antivir Ther. 2015;20(3):317-27. doi: 10.3851/IMP2885.

PMID:
25321623
10.

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.

Olin JL, Spooner LM, Klibanov OM.

Ann Pharmacother. 2012 Dec;46(12):1671-7. doi: 10.1345/aph.1R468. Review.

PMID:
23136357
12.

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.

Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK, Fordyce MW, Szwarcberg J; GS-236-0103 Study Team..

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):483-6. doi: 10.1097/QAI.0b013e318286415c.

PMID:
23337366
13.

Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.

Temesgen Z.

Drugs Today (Barc). 2012 Dec;48(12):765-71. doi: 10.1358/dot.2012.48.12.1895682. Review.

PMID:
23243633
14.

Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.

Andreatta K, Kulkarni R, Abram ME, Nguyen T, Cao H, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):519-26. doi: 10.1097/QAI.0000000000000503.

PMID:
25559592
15.

HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.

Andreatta K, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):367-74. doi: 10.1097/QAI.0b013e31827b55f1.

PMID:
23187937
16.

Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.

Klibanov OM.

Curr Opin Investig Drugs. 2009 Feb;10(2):190-200.

PMID:
19197797
17.

Raltegravir: the first HIV integrase inhibitor.

Cocohoba J, Dong BJ.

Clin Ther. 2008 Oct;30(10):1747-65. doi: 10.1016/j.clinthera.2008.10.012. Review.

PMID:
19014832
19.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
20.

Elvitegravir: a review of its use in adults with HIV-1 infection.

Deeks ED.

Drugs. 2014 Apr;74(6):687-97. doi: 10.1007/s40265-014-0206-8. Review.

PMID:
24671908
Items per page

Supplemental Content

Support Center